Drug
Sepantronium clinical trials
Also written YM155.
- studies test it
- 11
- open now
- 0
- in phase 3
- 0
- first study started
- 2005
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2009 (4)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 1 |
| 2009 | 4 |
| 2010 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 1
Astellas Pharma Inc (9) · Cothera Bioscience, Inc (1) · National Cancer Institute (NCI) (1)
Often tested with
Tested in the same studies.
Carboplatin (1) · Paclitaxel (1) · Rituximab (1) · Docetaxel (1)
Studies
Open first, then newest update. How each study uses sepantronium is read from its arms, and is right about nine times in ten.
Testing it · 11
- Sepantronium Bromide for the Treatment of High-grade B-cell LymphomaActive, not recruitingPhase 2Cothera Bioscience, IncNCT05263583Written as Sepantronium Bromide
- A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)CompletedPhase 1/2National Cancer Institute (NCI)NCT01100931Written as YM155
- A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior TreatmentCompletedPhase 2Astellas Pharma IncNCT01007292Written as YM155
- An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155CompletedPhase 2Astellas Pharma IncNCT00818480Written as YM155
- A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV MelanomaCompletedPhase 2Astellas Pharma IncNCT01009775Written as YM155
- Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) SubjectsTerminatedPhase 2Astellas Pharma IncNCT00498914Written as YM155
- A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast CancerCompletedPhase 2Astellas Pharma IncNCT01038804Written as YM155
- A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV MelanomaCompletedPhase 2Astellas Pharma IncNCT00281541Written as YM155
- A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With ChemotherapyCompletedPhase 2Astellas Pharma IncNCT00257478Written as YM155
- A Clinical Pharmacological Study of YM155 After Intravenous Infusion in Patients With Advanced CancerCompletedPhase 1Astellas Pharma IncNCT01023386Written as YM155
- LUCY: A Study for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in Patients Previously Treated With ChemotherapyCompletedPhase 2Astellas Pharma IncNCT00328588Written as YM155
Given in every arm · 1 — sepantronium is usual care beside what is tested
Codes
What other systems call sepantronium · ClinicalTrials.gg INT005175
- MeSH (NLM) C523798sepantroniumOne source NLM
- UNII (FDA) UZ77T1VFBMSEPANTRONIUMConfirmed FDA, NLM, Wikidata
- Wikidata Q27166390sepantroniumConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152335SepantroniumOne source FDA
- DrugBank DB17062One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C523798 | sepantronium | One source NLM |
| UNII (FDA) | UZ77T1VFBM | SEPANTRONIUM | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27166390 | sepantronium | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152335 | Sepantronium | One source FDA |
| DrugBank | DB17062 | — | One source Wikidata |
Also registered as sepantronium bromide (UNII 7H5Q4J1CM5).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.